US EditionFDA approves Moderna’s new lower-dose COVID-19 vaccine
- The FDA approved Moderna's new COVID-19 vaccine, mNexspike, late Friday for adults 65 and older and high-risk people ages 12 to 64.
- This approval follows a clinical trial of 11,400 people comparing mNexspike with Moderna's existing vaccine, and introduces new FDA limits on who can use it.
- MNexspike uses a dose one-fifth the size of Spikevax, Moderna's current vaccine, and targets the immune response more precisely as a next-generation option.
- Moderna CEO Stéphane Bancel stated that the FDA's authorization of their third vaccine, mNEXSPIKE, provides a valuable option aimed at safeguarding individuals most vulnerable to severe COVID-19 illness.
- Because of the FDA restrictions, mNexspike will supplement rather than replace Spikevax, suggesting a more targeted approach to vaccine use in high-risk groups.
130 Articles
130 Articles
FDA approves Moderna's new COVID-19 vaccine
ABC News reports that the U.S. Food and Drug Administration (FDA) has approved a new, lower-dose version of Moderna’s COVID-19 vaccine. This updated vaccine is designed to provide continued protection against current variants of the virus while potentially reducing side effects due to its lower dosage. The approval comes as part of ongoing efforts to […]
FDA grants limited approval to new Covid vaccine from Moderna
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical condition that increases their risk for severe Covid.
FDA Approves Moderna's Next-Gen COVID-19 Vaccine For High-Risk Groups
The Food and Drug Administration (FDA) has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for specific high-risk populations, the company announced Saturday. This marks a significant development as it’s the first such approval since the FDA implemented more stringent standards for COVID-19 vaccine authorization. The newly approved vaccine is cleared for adults aged 65 and older, […] FDA Approves Moderna’s Next-Gen COVID-19 Vacci…
US Authorizes Moderna's New COVID-19 Vaccine, mNexspike, With Usage Constraints - Real News Now
The United States granted authorization to Moderna’s novel COVID-19 vaccine, named mNexspike, albeit with certain usage constraints, late on a Friday. Rather than a replacement, it is designed to be an alternative to the organization’s existing vaccine. This recent development in the fight against the global pandemic illuminates a progression towards next-level virus defenses. The mNexspike vaccine stands out due to its unique manufacturing appr…
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
